Ivetra/Ivetra-100/Ivetra IV

Ivetra/Ivetra-100/Ivetra IV Indications/Uses

levetiracetam

Manufacturer:

Torrent

Distributor:

Torrent
Full Prescribing Info
Indications/Uses
Ivetra 250/Ivetra 500/Ivetra 1000/Ivetra-100: Levetiracetam indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Levetiracetam is indicated as adjunctive therapy: In the treatment of partial onset seizures with or without secondary generalisation in adults and children from 1 month of age with epilepsy.
In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Ivetra-IV: Levetiracetam Oral Solution concentrate is an alternative for patients (adults and children from 4 years of age) when oral administration is temporarily not feasible.
Ivetra IV: Partial Onset Seizures: It is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 1 month of age and older with epilepsy. Levetiracetam injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible.
Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy: It is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. Levetiracetam injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible.
Primary Generalized Tonic-Clonic Seizures: Indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. Levetiracetam injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in